India, July 28 -- Drug major GlaxoSmithKline plc (GSK,GSK.L) and Vir Biotechnology, Inc. (VIR) announced Wednesday that they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of COVID-19 treatment sotrovimab.
Sotrovimab is an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.
Under the deal, the participating EU Member States will be able to quickly purchase sotrovimab, following local emergency authorization or authorization at the EU level, to treat high-risk patients with COVID-19 who may benefit from early treatment with sot...